Rutgers is leading a clinical trial assessing the combination of nitazoxanide, ribavirin and hydroxychloroquine to treat people 21 or older who are infected with SARS-CoV-2 and are asymptomatic or mildly symptomatic. The trial is being conducted with Synavir Corporation, a global health company that works with academia, industry and government to develop combination treatments for new viral infections. The trial — called Triple Combination Antiviral Coronavirus Therapy (TriACT) — seeks to determine whether treating people who test positive for coronavirus but who do not have symptoms or have mild symptoms with this combination will reduce the amount of virus and their chances of getting sick. To read the full story.
- To Reduce Smoking Rates in Prisons, Cessation Programs Must Be Expanded and Extended.
- Rutgers Selected as Backup Center for New National 9-8-8 Mental Health Crisis Line.
- New NJACTS Publication
- Why do some people evade COVID-19 while others get reinfected?
- Rutgers Scientist Who Researches the Sense of Smell Named Rita Allen Foundation Scholar.